戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 rves) and a diabetic neuropathy model (i.e., streptozotocin-induced diabetes).
2  co-induced in livers of mice in response to streptozotocin induced diabetes.
3  in transgenic mice, which were resistant to streptozotocin-induced diabetes.
4 etinal microvascular cells after 5 months of streptozotocin-induced diabetes.
5  is markedly reduced soon after the onset of streptozotocin-induced diabetes.
6 cible human Nox5 transgenic mouse exposed to streptozotocin-induced diabetes.
7 pose tissue LPL expression in male rats with streptozotocin-induced diabetes.
8 ed in coronary venules at the early onset of streptozotocin-induced diabetes.
9 yte stasis (leukostasis) in the rat model of streptozotocin-induced diabetes.
10 c pancreata were transplanted into mice with streptozotocin-induced diabetes.
11 ancreatic protein using acini from rats with streptozotocin-induced diabetes.
12 oglycemia for more than 80 days in mice with streptozotocin-induced diabetes.
13 ects, and granulation tissues from mice with streptozotocin-induced diabetes.
14 gy in rat models of ischemia-reperfusion and streptozotocin-induced diabetes.
15 SCHAD knockout (SCHADKO) mice into mice with streptozotocin-induced diabetes.
16 nal brush border membrane (BBM) of mice with streptozotocin-induced diabetes.
17 iferative islet cells and with resistance to streptozotocin-induced diabetes.
18 hyperglycemia and ex vivo, in a rat model of streptozotocin-induced diabetes.
19 iminished opioid responsiveness in rats with streptozotocin-induced diabetes.
20 in situ and by glycemic control in rats with streptozotocin-induced diabetes.
21 lar leakage in both early and late stages of streptozotocin-induced diabetes.
22 so observed in liver extracts from mice with streptozotocin-induced diabetes.
23 eability (RVP) and hemodynamics in rats with streptozotocin-induced diabetes.
24 ture healing in a model of multiple low-dose streptozotocin-induced diabetes.
25  a more severe hyperglycemia associated with streptozotocin-induced diabetes.
26 duced obesity and insulin resistance or with streptozotocin-induced diabetes.
27 ibitor apocynin in models of endotoxemia and streptozotocin-induced diabetes.
28 he epididymal fat pad of syngeneic mice with streptozotocin-induced diabetes.
29       Moreover, HcB-19 mice are resistant to streptozotocin-induced diabetes.
30 x1) to ameliorate hyperglycemia in mice with streptozotocin-induced diabetes.
31 N loss also protects animals from developing streptozotocin-induced diabetes.
32  in whole retinas after 2, 4, and 8 weeks of streptozotocin-induced diabetes.
33 Pten mutant mice are resistant to developing streptozotocin-induced diabetes.
34 rated in vivo function and were able to cure streptozotocin-induced diabetes.
35 not exacerbate retinal endothelial injury in streptozotocin-induced diabetes.
36 f these NF-kappaB subunits were resistant to streptozotocin-induced diabetes.
37 evel is increased in the livers of rats with streptozotocin-induced diabetes.
38 g were evaluated in C57BL/6J adult mice with streptozotocin-induced diabetes.
39  observed in rats with a 10-week duration of streptozotocin-induced diabetes.
40 creased HbA(1c) levels in the mouse model of streptozotocin-induced diabetes.
41 ponsible for the hyperfiltration observed in streptozotocin-induced diabetes; (2) a combined alterati
42  assessed whether CNTF protects mice against streptozotocin-induced diabetes (a model of type 1 diabe
43        c-Rel-deficient mice are resistant to streptozotocin-induced diabetes, a drug-induced model of
44 ective of this study is to determine whether streptozotocin-induced diabetes activates cell death pat
45                            After 16 weeks of streptozotocin-induced diabetes, albuminuria and renal h
46                             After 2 weeks of streptozotocin-induced diabetes, analysis of albumin lea
47 e of 7 nontreated, nontransplanted mice with streptozotocin-induced diabetes and 7 normal mice), demo
48  PPARa signaling were further compromised by streptozotocin-induced diabetes and ameliorated by feedi
49 Ralpha signaling were further compromised by streptozotocin-induced diabetes and ameliorated by feedi
50  vessels isolated from rats with 6 months of streptozotocin-induced diabetes and compared it with tha
51 ofiling of glomeruli isolated from rats with streptozotocin-induced diabetes and controls.
52 rsensitive to collagen-induced arthritis and streptozotocin-induced diabetes and develop heightened a
53 tions were prepared from retina of rats with streptozotocin-induced diabetes and from the isolated re
54                        Rats with 10 weeks of streptozotocin-induced diabetes and GHb levels of 16 +/-
55 diabetes, examining the kidneys of rats with streptozotocin-induced diabetes and kidney cells exposed
56 ing VDR in beta-cells were protected against streptozotocin-induced diabetes and presented a preserve
57                                              Streptozotocin-induced diabetes and retinal ischemia-rep
58 the pathogenesis of murine multiple low-dose streptozotocin-induced diabetes and support the concept
59 in dorsal root ganglion neurons in rats with streptozotocin-induced diabetes and tactile allodynia, u
60 ively expressed in beta cells prevented both streptozotocin-induced diabetes and the metabolic defici
61  transplanted into immunodeficient mice with streptozotocin-induced diabetes, and glycemia was initia
62 -reperfusion between control rats, rats with streptozotocin-induced diabetes, and rats with hyperglyc
63 sed islet cell mass and improved outcomes in streptozotocin-induced diabetes at 8 weeks of age.
64 leukocyte 12-LO in mice ameliorates low dose streptozotocin-induced diabetes by increasing islet resi
65    In conclusion, CNTF protects mice against streptozotocin-induced diabetes by increasing pancreatic
66                               Starvation and streptozotocin-induced diabetes cause decreases in PDP2
67                                              Streptozotocin-induced diabetes caused GPR91-dependent u
68                   Our findings indicate that streptozotocin-induced diabetes causes the insertion of
69 alogue, was markedly attenuated in rats with streptozotocin-induced diabetes, consistent with a profo
70 % (P < 0.01) in apoE knockout (KO) mice with streptozotocin-induced diabetes consuming an atherogenic
71 GR5 dual agonist INT-767 to DBA/2J mice with streptozotocin-induced diabetes, db/db mice with type 2
72                                    Mice with streptozotocin-induced diabetes developed profound heart
73 48 only (B48 mice) to examine the effects of streptozotocin-induced diabetes (DM) on apoB-100- and ap
74 (AC) ), under three experimental conditions (streptozotocin-induced diabetes, during normal aging, an
75                Rats with 1, 2, or 4 weeks of streptozotocin-induced diabetes exhibited significantly
76                       Following the onset of streptozotocin-induced diabetes, FasL expression was inc
77                Subjecting Nox5(pod+) mice to streptozotocin-induced diabetes further exacerbated thes
78 comorbid diabetes (aging, high-fat diet, and streptozotocin-induced diabetes) had heightened lung ACE
79 e unchanged during chronic food restriction, streptozotocin-induced diabetes, hypoglycemia when food
80 e retinas of rats with 2 months' duration of streptozotocin-induced diabetes, IGF-I mRNA levels were
81 asting, increased by insulin, and reduced by streptozotocin-induced diabetes, implicating FGFR4 as a
82 cose levels in two mouse models of IDDM: (1) streptozotocin-induced diabetes in C57BL/6J mice on a re
83 volved in leukostasis in the early stages of streptozotocin-induced diabetes in mice by direct observ
84 ype I diabetes, we studied multiple low-dose streptozotocin-induced diabetes in mice deficient in eit
85                                We found that streptozotocin-induced diabetes in mice skewed hematopoi
86                                              Streptozotocin-induced diabetes in rats resulted in a de
87                            Three weeks after streptozotocin-induced diabetes in rats, we found a pref
88 th factors in FP engraftment and reversal of streptozotocin-induced diabetes in rats.
89                                           In streptozotocin-induced diabetes in the rat, there were m
90 e ability of 6-month cultured islets to cure streptozotocin-induced diabetes in this mouse model.
91 , we assessed the consequence of 4 months of streptozotocin-induced diabetes in wild type (+/+) and C
92                                              Streptozotocin-induced diabetes increased glomerular cap
93 onsecutive days in an in vivo mouse model of streptozotocin-induced diabetes inhibited the loss of ti
94 ss GFP driven by the mouse insulin promoter, streptozotocin-induced diabetes led to the appearance of
95 poE(-/-)) mice (n = 22), including mice with streptozotocin-induced diabetes mellitus (n = 8), nondia
96                  For this purpose, rats with streptozotocin-induced diabetes mellitus (STZ-DM) were t
97  were reduced in the myocardium of mice with streptozotocin-induced diabetes mellitus as compared to
98                                              Streptozotocin-induced diabetes mellitus in animals lead
99                                              Streptozotocin-induced diabetes mellitus in mice was stu
100                   In rats rendered diabetic (streptozotocin-induced diabetes mellitus) wound healing
101 fasted mice, from rats with cancer cachexia, streptozotocin-induced diabetes mellitus, uremia induced
102 in the hyperfiltration observed in rats with streptozotocin-induced diabetes mellitus.
103 GTPCH and BH4 and endothelial dysfunction in streptozotocin-induced diabetes mellitus.
104                                In a model of streptozotocin-induced diabetes, miR-146a(-/-) mice show
105  the role of PTX3 within DR, we employed the streptozotocin-induced diabetes model in PTX3 knockout m
106                                    Using the streptozotocin-induced diabetes mouse model, we administ
107                                 In rats with streptozotocin-induced diabetes, nitric oxide (NO) bioav
108 e mouse models of insulin action deficiency: streptozotocin-induced diabetes, ob/ob genotype and live
109 lar tissues of normal rats, and in rats with streptozotocin-induced diabetes of 6 and 12 weeks' durat
110                                              Streptozotocin-induced diabetes of a 2-week or 2-month d
111 present study was to determine the effect of streptozotocin-induced diabetes on BBM glucose transport
112                               The effects of streptozotocin-induced diabetes on the electrophysiologi
113 the corneal clock, we studied the effects of streptozotocin-induced diabetes on the mitosis of epithe
114                 rPdx1 treatment of mice with streptozotocin-induced diabetes promotes beta-cell regen
115                            After 6 months of streptozotocin-induced diabetes, rats (n = 12) and age-m
116                                  At 15 wk of streptozotocin-induced diabetes, renal expression of BMP
117  were able to protect recipient mice against streptozotocin-induced diabetes, restoring a physiologic
118              In the absence of hypertension, streptozotocin-induced diabetes resulted in a 14-fold in
119 egrees C, degrees C into 42 B6AF/1 mice with streptozotocin-induced diabetes resulted in a return to
120                                              Streptozotocin-induced diabetes resulted in increased ex
121 c BB rats, we have found that 8-10 months of streptozotocin-induced diabetes results in fewer dystrop
122 ning porcine islets for 17 days in rats with streptozotocin-induced diabetes results in normalization
123                            RAGE-/- mice with streptozotocin-induced diabetes showed delayed rejection
124                                 In pigs with streptozotocin-induced diabetes, superoxide formation wa
125 p53inp2 exhibited enhanced muscle wasting in streptozotocin-induced diabetes that was dependent on au
126                            After 13 weeks of streptozotocin-induced diabetes, the activity of this tr
127                                 In rats with streptozotocin-induced diabetes, the centrifugal axon te
128             In this study, we used mice with streptozotocin-induced diabetes treated with the SGLT2i
129 ge was evaluated in db/db mice and rats with streptozotocin-induced diabetes using the Evans Blue met
130                             A mouse model of streptozotocin induced diabetes was used that expresses
131                                              Streptozotocin-induced diabetes was associated with a si
132 of six pairs of cynomolgus monkeys (CM) with streptozotocin-induced diabetes was closely matched for
133 traperitoneal rPdx1 injection into mice with streptozotocin-induced diabetes, we assessed its action
134                                 In rats with streptozotocin-induced diabetes, we measured increased (
135                       Using a rat model with streptozotocin-induced diabetes, we measured the effects
136 in D (CypD)-deficient mice (Ppif (-/-)) with streptozotocin-induced diabetes, we observed an increase
137 n neurons and the GABAB)receptor function in streptozotocin-induced diabetes, we performed whole-cell
138                                    Rats with streptozotocin-induced diabetes were also fed saturated
139                                    Rats with streptozotocin-induced diabetes were in a state of poor
140 tic RAGE apoE double-knockout (KO) mice with streptozotocin-induced diabetes were treated with the AG

 
Page Top